產(chǎn)品詳情
簡單介紹：
重組人白細(xì)胞介素-36受體拮抗劑蛋白蛋白與其它公司提供的重組蛋白不同，rHuIL-36RA蛋白產(chǎn)品為采用CFS的無細(xì)胞麥胚蛋白合成系統(tǒng)表達(dá)出來的重組蛋白，可表達(dá)出對細(xì)胞有毒性、易被蛋白酶降解的蛋白；并獲得具有良好的可溶性，并有翻譯后修飾、從而部分具有功能的蛋白.同時獨有的全自動蛋白純化技術(shù)則簡便高效，將蛋白純化過程中對蛋白的損傷降低到*小程度.重組人白細(xì)胞介素-36受體拮抗劑蛋白蛋白（全長序列）產(chǎn)品可用于Western Blot驗證、抗體制備、蛋白檢測、ELISA等試驗中.
詳情介紹：
重組人白細(xì)胞介素-36受體拮抗劑蛋白蛋白
| Synonyms | IL-1RP3, IL-1HY1, IL-1 delta, IL-1F5, IL-1ra homolog 1, IL-1L1 |
| Species | Human |
| Accession | Q9UBH0 |
| GeneID | 26525 |
| Source | Escherichia coli. |
| Molecular Weight | 重組人白細(xì)胞介素-36受體拮抗劑蛋白蛋白Approximately 16.8 kDa, a single non-glycosylated polypeptide chain containing 154 amino acids. |
| Quantity | 5μg/25μg/1000μg |
| AA Sequence | VLSGALCFRM KDSALKVLYL HNNQLLAGGL HAGKVIKGEE ISVVPNRWLD ASLSPVILGV QGGSQCLSCG VGQEPTLTLE PVNIMELYLG AKESKSFTFY RRDMGLTSSF ESAAYPGWFL CTVPEADQPV RLTQLPENGG WNAPITDFYF QQCD |
| Purity | 重組人白細(xì)胞介素-36受體拮抗劑蛋白蛋白> 95 % by SDS-PAGE and HPLC analyses. |
| Biological Activity | Fully biologically active when compared to standard. The ED50 as determined by inhibiting IL-36 beta induced IL-8 secretion by human preadipocytes is less than 1.0 μg/ml, corresponding to a specific activity of > 1000 IU/mg in the presence of 20 ng/ml of recombinant human IL-36 beta. |
| Physical Appearance | Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation | 重組人白細(xì)胞介素-36受體拮抗劑蛋白蛋白Lyophilized from a 0.2 μm filtered concentrated solution in PBS, pH 7.4. |
| Endotoxin | Less than 1 EU/μg of rHuIL-36RA as determined by LAL method. |
| Reconstitution | We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions. |
| Storage | This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles. |
| 重組人白細(xì)胞介素-36受體拮抗劑蛋白蛋白 | |
| SDS-PAGE |
|
| Reference |
1. Born TL, Smith DE, Garka KE, et al. 2000. J Biol Chem. 275:41528. 2. Dunn EF, Gay NJ, Bristow AF, et al. 2003. Biochemistry. 42:10938-44. 3. Barton JL, Herbst R, Bosisio D, et al. 2000. Eur J Immunol. 30:3299-308. 4. Debets R, Timans JC, Homey B, et al. 2001. J Immunol. 167:1440-6. 5. Towne JE, Renshaw BR, Douangpanya J, et al. 2011. J Biol Chem. 286:42594-602. |
| Background | Interleukin-36 receptor antagonist (IL-36RA) is a secreted protein which belongs to the interleukin 1 cytokine family (IL-1 family) and it is predominantly expressed in keratinocytes but not in fibroblasts, endothelial cells or melanocytes. IL-36RA has been reported to antagonize the biological activity of IL-36α (IL-1F6), IL-36β (IL-1F8), and IL-36γ (IL-1F9). Furthermore, it could constitute part of an independent signaling system analogous to interleukin-1 alpha (IL-1A), beta (IL-1B) receptor agonist and interleukin-1 receptor type I (IL-1R1). In addition, The receptor for IL-36RA has not been positively identified. Indirect evidence suggests it is IL-1Rrp2. Recombinant human IL-36 RA contains 154 amino acid residues and it shares 91 % a.a. sequence identity with murine IL-36RA. |
